Approval · Notice of Compliance 28100 · 2022
BREYANZI: Notice of Compliance 28100
Issued May 6, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28100
- Date
- May 6, 2022
- Company
- Celgene IncSaint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BREYANZI | 02527138 | Marketed |
Medicinal ingredients
- LISOCABTAGENE MARALEUCEL 120,000,000 CELLS per DOSE